The effect of Aromix gel on pain caused by knee osteoarthritis

Comparing the effect of Aromix Barij Gel ® and Diclophenac Gel in patiants that affected to knee osteoarthritis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220512054829N5

Enrollment

Registered

2025-08-12

Start date

2025-08-23

Completion date

Unknown

Last updated

2025-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis of knee, unspecified. Osteoarthritis of knee, unspecified

Interventions

Intervention 1: Intervention group: Aromix topical gel manufactured by Barij Essence Pharmaceutical Company, used twice daily or when knee pain occurs, for one month. Intervention 2: Control group: Di

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Osteoarthritis patients according to the criteria of the American College of Rheumatology Age 18-80 years Pain in at least one knee in the past month

Exclusion criteria

Exclusion criteria: Patients who are in the acute phase of knee arthritis or have secondary osteoarthritis (such as rheumatological diseases and severe joint trauma) Osteoarticular diseases (rheumatoid arthritis, gout) History of psychosomatic illness Acute phase of knee arthritis or secondary osteoarthritis Suffering from osteoarticular diseases (rheumatoid arthritis, gout) Uncontrolled high blood pressure (above 90/140 mmHg) CHF functional class three or four New York Association class Movement disorder due to a cause other than knee osteoarthritis and hip Pregnancy Lactation Intra-articular drug injection Use of another analgesic

Design outcomes

Primary

Measure	Time frame
Clinical sign. Timepoint: Before treatment and 2th and 4th weeks after treatment. Method of measurement: WOMAC instrument.;Pain. Timepoint: Before treatment and 2th and 4th weeks after treatment. Method of measurement: WOMAC instrument.;Morning dryness. Timepoint: Before treatment and 2th and 4th weeks after treatment. Method of measurement: WOMAC instrument.;Function - Daily Life. Timepoint: Before treatment and 2th and 4th weeks after treatment. Method of measurement: WOMAC instrument.;Pain or discomfort. Timepoint: Before treatment and 2th and 4th weeks after treatment. Method of measurement: Lequesne index.	—

Measure

Time frame

Clinical sign. Timepoint: Before treatment and 2th and 4th weeks after treatment. Method of measurement: WOMAC instrument.;Pain. Timepoint: Before treatment and 2th and 4th weeks after treatment. Method of measurement: WOMAC instrument.;Morning dryness. Timepoint: Before treatment and 2th and 4th weeks after treatment. Method of measurement: WOMAC instrument.;Function - Daily Life. Timepoint: Before treatment and 2th and 4th weeks after treatment. Method of measurement: WOMAC instrument.;Pain or discomfort. Timepoint: Before treatment and 2th and 4th weeks after treatment. Method of measurement: Lequesne index.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHossein Akbari

Kashan University of Medical Sciences

akbari1350_h@yahoo.com+98 31 5558 9396

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026